Cyclic Low Dose Naltrexone In Cancer

4 Jul 2023 · 1 min

Watch on YouTube

0:59

In this segment, the speaker reviews published in‑vitro research comparing continuous low‑dose naltrexone (LDN) exposure to a cyclic dosing approach in cancer cell lines. The data show that cycling the dose—providing a drug‑free break—produces a markedly greater increase in cancer cell death than continuous exposure. Although in‑vitro findings often fail to translate clinically, the magnitude of the observed effect convinced the speaker to adopt a cyclic LDN protocol for all of his oncology patients. He describes a practical regimen: a 4.5 mg LDN dose taken Monday through Friday with a two‑day weekend break (5 days on, 2 days off), emphasizing simplicity and patient adherence.

Chapters

data that was published that looked at continuous low-dose naltrexone dosing in cancer cell lines and then cyclic dosing. And a lot of in vitro studies don't really translate, but when you look at the magnitude of the effect on the cancer cells by simply cycling the dose of naltrexone and having a break versus continuous dosing with naltrexone, the magnitude of change in cancer cell death, etc., is so large that it is compelling enough to me that these, these past— we're about 6 years in now knowing this data— I've shifted all of my oncology patients to a cyclic dose. Now, keeping things as easy as possible is the best thing. So let's say they're on a 4.5 milligram dose and they have cancer. What we will do is we'll tell them, you're going to take your naltrexone Monday through Friday, and then you're just going to take a break on the weekend. So it's 5 days on and 2 days off.